Argos Therapeutics, Inc. announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). The update will be presented in a poster presentation entitled "ADAPT: An Ongoing International Phase III Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment in Advanced Renal Cell Carcinoma (RCC)"during General Poster Session C at the Genitourinary Cancers Symposium being held in San Francisco. The ADAPT study is a randomized, multicenter, open-label clinical trial designed to evaluate AGS-003, an investigational, fully personalized immunotherapy, in combination with standard targeted drug therapy, to determine the potential to extend overall survival in newly-diagnosed, intermediate and poor risk mRCC patients.

Secondary endpoints in this study include progression-free survival, safety, overall response and immune response. The ADAPT trial is expected to enroll 450 patients in approximately 140 sites in North America, Europe, and Israel under an approved Special Protocol Assessment by the U.S. Food & Drug Administration. As previously announced, Argos remains on track to complete enrollment in the ADAPT trial by the end of 2014.

To create AGS-003, ribonucleic acid (RNA) is isolated from a small tumor sample obtained from standard tumor removal surgery (nephrectomy). The patient's dendritic cells are obtained from a single leukapheresis procedure. The tumor RNA is used to program these further optimized dendritic cells with the entire disease-antigen repertoire to trigger an immune response against the patient's specific cancer.